Vimian Group AB (VIMIAN) AI Stock Analysis

• Market Cap: €17.22B
• Dividend Yield: N/A
• Average Volume (3M): 721.77K
• Price to Earnings (P/E): 66.8
• Beta (1Y): 0.61
• Revenue Growth: 15.07%
• EPS Growth: 117.65%
• Country: SE
• Employees: 1,200
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.32
• Shares Outstanding: 525,964,540
• 10 Day Avg. Volume: 452,014
• 30 Day Avg. Volume: 721,768
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €36.53
• Price Target Upside: 15.75% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 57 Neutral
• Price Target: kr34.00 ▲(7.73% Upside)

Vimian Group AB's overall stock score is primarily influenced by its solid financial performance, which is offset by bearish technical indicators and a high P/E ratio suggesting overvaluation. The lack of earnings call data and corporate events means these factors do not impact the score.

Positive Factors

Acquisition

Vimian announced the acquisition of AllAccem Inc., a US-based company focused on veterinary dental care, with an EBITDA margin well above group average.

Organic Growth

The company achieved 5% organic growth at the group level, driven by increases in Specialty Pharma, Veterinary Services, and Diagnostics.

Stock Listing

The Listing Committee of Nasdaq Stockholm approved Vimian's application to be listed on the Nasdaq Stockholm Main Market in the Large Cap segment, which is expected to improve liquidity in the shares and elevate the company's profile.

Negative Factors

CEO Change

The combination of an earnings miss and abrupt CEO change is likely to weigh on investor sentiment in the trading session.

Earnings Performance

Vimian’s 2Q25 results came in below expectations, with net sales up 15% year-over-year to EUR 104.3m, mainly due to weaker-than-expected results in Specialty Pharma and MedTech.

MedTech Performance

MedTech saw a 12% organic decline from the final phase out of the AOP and a soft US surgery market.

Vimian Group AB Business Overview & Revenue Model

Company Description

Vimian Group AB (VIMIAN) is a global veterinary services company specializing in providing products and solutions across various segments of animal health. The company operates through several key sectors, including specialty pharma, diagnostics, veterinary services, and medtech. Vimian's core offerings include advanced pharmaceuticals, diagnostic tools, and medical technologies designed to enhance the well-being and treatment of animals worldwide.

How the Company Makes Money

Vimian Group AB generates revenue through a diversified portfolio of products and services in the animal health industry. The company earns money primarily by selling pharmaceuticals, diagnostic equipment, and medical devices to veterinary clinics and animal hospitals. Additionally, Vimian offers specialized veterinary services that contribute to its income. The company's revenue streams are further supported by strategic partnerships with other leading firms in the veterinary sector, which enhance its product offerings and market reach. Key factors such as the increasing demand for advanced animal healthcare solutions and a growing pet population contribute significantly to Vimian's earnings.

Vimian Group AB Financial Statement Overview

Summary

Vimian Group AB exhibits solid financial performance with consistent revenue growth and strong cash flow generation. Profitability margins are stable, but there is room for improvement in net profit margins. The balance sheet reflects a prudent leverage strategy, though returns on equity could be enhanced.

Income Statement

Vimian Group AB shows a consistent revenue growth trajectory, with a TTM revenue growth rate of 3.4%. Gross profit margins remain strong at approximately 68.7%, indicating efficient cost management. However, net profit margins are relatively low at 5.6%, suggesting room for improvement in profitability. EBIT and EBITDA margins are stable, reflecting operational efficiency.

Balance Sheet

The company's debt-to-equity ratio is moderate at 0.43, indicating a balanced approach to leveraging. Return on equity is low at 3.3%, suggesting limited returns for shareholders. The equity ratio stands at 60.1%, showing a solid equity base relative to total assets, which enhances financial stability.

Cash Flow

Vimian Group AB demonstrates strong cash flow management with a significant free cash flow growth rate of 29.3% in the TTM period. The operating cash flow to net income ratio is healthy at 0.85, indicating efficient cash generation relative to net income. The free cash flow to net income ratio is robust at 0.84, reflecting strong cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	404.35M	374.80M	331.73M	281.31M	173.35M	137.75M
Gross Profit	277.82M	258.30M	229.43M	193.99M	122.85M	95.52M
EBITDA	87.72M	82.80M	69.19M	66.32M	40.98M	65.16M
Net Income	22.67M	18.50M	9.84M	-7.20M	6.59M	52.79M
Balance Sheet
Total Assets	1.14B	1.11B	973.68M	923.56M	640.72M	456.29M
Cash, Cash Equivalents and Short-Term Investments	67.50M	64.80M	37.50M	42.19M	55.11M	29.66M
Total Debt	294.00M	233.60M	313.80M	220.96M	180.37M	85.91M
Total Liabilities	444.80M	403.30M	446.97M	442.06M	282.08M	182.05M
Stockholders Equity	682.90M	699.90M	526.37M	481.81M	357.41M	224.02M
Cash Flow
Free Cash Flow	67.15M	43.90M	-43.48M	15.01M	4.52M	-793.00K
Operating Cash Flow	80.38M	58.10M	-28.58M	25.31M	16.01M	4.80M
Investing Cash Flow	-148.90M	-76.00M	-77.68M	-188.53M	-115.00M	-105.24M
Financing Cash Flow	97.10M	44.80M	100.55M	150.23M	123.94M	118.57M

Vimian Group AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 31.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIMIAN, the sentiment is Negative. The current price of 31.56 is below the 20-day moving average (MA) of 32.01, below the 50-day MA of 36.52, and below the 200-day MA of 39.54, indicating a bearish trend. The MACD of -1.14 indicates Negative momentum. The RSI at 36.19 is Neutral, neither overbought nor oversold. The STOCH value of 65.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VIMIAN.

Vimian Group AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIMIAN	57 Neutral	€17.22B	66.78	3.34%	―	15.07%	117.65%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
0O5H	―	kr18.63B	79.46	2.43%	―	―	―
0YAY	―	kr18.33B	40.64	3.46%	5.60%	―	―
ADDLF	―	$2.24B	68.51	6.27%	0.19%	―	―
NLTBF	―	$1.64B	22.91	13.55%	2.54%	―	―
61MA	―	€844.82M	47.05	15.85%	―	―	―

Vimian Group AB Corporate Events

Vimian Group AB Increases Shares and Voting Power

Vimian Group AB announced an increase in the number of shares and votes due to the exercise of warrants and conversion of class C shares into ordinary shares. This change reflects the company’s strategic financial adjustments and may impact its market positioning by enhancing shareholder value and voting power distribution.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group CEO Resigns; Interim Leadership Appointed

Vimian Group AB announced the immediate resignation of CEO Patrik Eriksson, with CFO Carl-Johan Zetterberg Boudrie stepping in as interim CEO. The company is initiating a search for a new CEO to drive its strategic focus on profitable growth and leveraging its global scale. The changes are part of Vimian’s efforts to strengthen its leadership and continue its growth trajectory in the animal health industry.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group to Release Q2 2025 Interim Report with Investor Audiocast

Vimian Group AB has announced the release of its Interim Report for the second quarter of 2025, scheduled for publication on July 18. The company will host an audiocast for investors, analysts, and media, where CEO Patrik Eriksson and CFO Carl-Johan Zetterberg Boudrie will present and discuss the report. This event underscores Vimian’s commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Expands Share Base with Warrant Exercise

Vimian Group AB announced an increase in its number of shares and votes following the exercise of warrants from a program approved in 2022. This change reflects the addition of 2,724,260 ordinary shares, bringing the total to 526,615,332 shares, with a corresponding increase in voting rights. This development may enhance Vimian’s market position by potentially increasing its capital base and shareholder engagement.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Launches Employee Incentive Program Subscription

Vimian Group AB has initiated the subscription period for its 2022-2025 incentive program, allowing employees to subscribe to shares through a warrant program. To support this, some warrant holders have sold shares, and Vimian’s major shareholder, Fidelio Vet Holding AB, facilitated the process by lending shares to the investment bank handling the transaction. This strategic move aims to enhance liquidity and ensure a smooth subscription process for both local and foreign warrant holders, maintaining Fidelio’s shareholding position.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Expands Dental Portfolio with AllAccem Acquisition

Vimian Group AB has announced the acquisition of AllAccem Inc., a leading provider of veterinary dental sealant products in the US, as part of its strategy to enhance its veterinary dental offerings. This acquisition, which will integrate AllAccem into Vimian’s MedTech segment, is expected to bolster Vimian’s position in the fast-growing niche of animal dental health, leveraging AllAccem’s high-margin products and strong market presence to improve global animal dental care.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group AB Adopts New Incentive Programs and Remuneration Guidelines

Vimian Group AB held an Extraordinary General Meeting on June 11, 2025, where shareholders approved several key resolutions. These included adopting new Articles of Association to introduce reclassifiable and redeemable share classes for the company’s incentive program, implementing a long-term performance-based share program for employees and consultants, and updating remuneration guidelines to allow for incentive programs to be adopted by both Annual and Extraordinary General Meetings. These changes are expected to enhance Vimian’s operational flexibility and align with local laws and practices, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group AB Successfully Issues EUR 150 Million in Bonds

Vimian Group AB has successfully issued EUR 150 million in senior unsecured bonds, significantly oversubscribed, with plans to list them on Nasdaq Stockholm. This move reflects strong investor confidence and is expected to enhance Vimian’s financial flexibility, supporting its growth in the animal health sector.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group AB Plans EUR 125 Million Bond Issuance

Vimian Group AB is considering issuing a senior unsecured bond to raise EUR 125 million, with a potential framework of EUR 250 million, subject to market conditions. The proceeds will be used to refinance existing debt and support corporate activities, including acquisitions and investments, potentially impacting its financial strategy and market positioning.